Nob Hill Therapeutics, an Albuquerque, NM-based an early-stage pulmonary medical system and therapeutics firm, raised $3M in Sequence A funding.
The spherical was led by Tramway Enterprise Companions and included investments from TCA Enterprise Group and VIC Know-how Enterprise Growth (which based NHT). In reference to the financing, Chris Japp, Managing Associate of Tramway Enterprise Companions, will be a part of Nob Hill’s Board of Administrators. Sima Ghafari of TCA Enterprise Group will be a part of as a Board Observer.
The corporate intends to make use of the funds for the continued improvement of its high-dose respiratory expertise and therapeutics, together with pre-IND research.
Led by CEO Noel Greenberger, Nob Hill Therapeutics is a respiratory-focused healthcare firm that makes use of excessive dose lung supply to deal with lung-related ailments. Its patented Dry Powder Nebulizer platform has a number of technological improvements that allow it to generate drug aerosols and ship them successfully to the decrease respiratory tract, impartial of the affected person’s lung capability.
NHT has a patent-protected inhalation system expertise able to delivering excessive therapeutic doses on to the lung. It’s appropriate for sufferers of all ages and inhalation capabilities, together with sufferers with compromised lung perform.
FinSMEs
06/08/2024
